A long-term study of the most widely used osteoporosis drug has found that many women can discontinue the drug after five years without increasing their fracture risk for as long as five more years.
Research by the Human Pain Research Group at the University of Manchester suggests that people’s responses to placebo or “dummy” pain relief varies according to their way of thinking.
The Food and Drug Administration (FDA) today approved Invega (paliperidone) extended-release tablets for the treatment of schizophrenia. Paliperidone is a new molecular entity, which means this medication contains an active substance that has never before been approved for marketing in any form in the United States.
Experiments on mouse models of Alzheimer’s disease suggest that treatment with male sex hormones might slow its progression. The findings, published in the Dec. 20 issue of the Journal of Neuroscience, provide new insight into the relationship between testosterone loss and AD, which affects 4.5 million Americans.
Researchers at the University of Maryland School of Medicine in Baltimore will begin a clinical trial in January to test the first cell culture-based pandemic influenza vaccine to see if it will provide immunity faster and more reliably than a vaccine produced in eggs. The new study is also the first test in the United States of a whole virus vaccine for avian influenza, which could produce a stronger response by the immune system.
The herbal supplement black cohosh does not relieve hot flashes among women going through menopause. In this double-blinded randomized controlled trial of 351 women, researchers found no significant difference between the numbers of hot flashes in women taking various forms of black cohosh compared to women taking a placebo. Hormone therapy, on the other hand, significantly reduced the frequency of hot flashes.
Agalsidease-beta therapy for Fabry disease slowed progression of kidney, heart and nervous system complications and death compared to placebo, a new study found.
Data from the HALT study, Herbal Alternatives for Menopause, found that black cohosh, in three formulations, was no better than placebo in reducing symptoms of hot flashes and night sweats during menopause.
The Food and Drug Administration (FDA) today approved Cyanokit (containing the drug hydroxocobalamin, intravenous tubing and a sterile spike for reconstituting the drug product with saline) for the treatment of known or suspected cyanide poisoning. The approval, which is based on evidence of the drug’s effectiveness when tested in animals, improves the nation’s ability to respond to emergencies, including a potential attack by terrorists.
New data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-33 study, presented today at the San Antonio Breast Cancer Symposium, showed that postmenopausal women with hormone receptor-positive breast cancer who received Aromasin after five years of tamoxifen were 56 percent less likely to have a relapse of breast cancer than those who received placebo.